Janssen speeds up guselkumab approval proc...Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications. more ➔
Abzenas partner True North Therapeutics...British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed … more ➔
RA: Sanofi/Regeneron IL-6R blocker FDA-app...Following the EMAs recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light … more ➔
Safety event delays US market approval of...Top-Line Phase 3 data of Amgens/UCBs osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal. more ➔
Vesalius Biocapital fund raises €65mLuxembourg-based venture capital specialist Vesalius Biocapital has closed the first round of Biocapital III fund that aims to invest into later-stage European life sciences companies. more ➔
Merck presents new CRISPR genome editing m...German Merck KGaA has developed a new genome editing tool dubbed proxy-CRISPR providing access to previously inaccessible microenviroments of the genome by modification of chromatin modification … more ➔
Astellas completes Ogeda takeoverAstellas Pharma Inc. has completed the acquisition of Ogeda SA (previously Euroscreen SA, Gosselies, Belgium). more ➔
Vifor Pharma acquires US$50m share in Akeb...Swiss Vifor Pharma has agreed to acquire shares of Cambridge-based distributor Adebia worth US$50m in order exclusivly distribute its hypoxia-inducible factor (HIF) stabiliser vadadustat to 40% of US … more ➔
NSCLC: AstraZenecas durvalumab meets PFS...AstraZenecas anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available. more ➔
Norgine to acquire Merus Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash. more ➔
